Alpha-Pinene Doses Were Anchored to a Product Sample, Not Every Cannabis Strain
The alpha-pinene trial’s lower doses were selected using chemical analyses of a particular cannabis sample collection. That makes the dose rationale concrete without making it a survey of every cannabis product.
The investigators used measured product composition
The methods describe analyses of 107 samples representing 29 cultivars sold by one licensed producer. The lower experimental amounts reflected the mean and maximum alpha-pinene amounts in one gram of flower within that collection. An additional higher dose expanded the tested range after pilot work.
A rationale is not a universal composition estimate
The collection helped select relevant experimental amounts. It did not establish the full distribution across all producers, regions, harvests or product types. Nor does a constituent amount in one gram specify the absorbed dose from smoking or vaporization.
Keep the dose range attached to the null result
The absence of the proposed memory protection was observed across the tested combinations, including an amount above those represented by the lower dose rationale. That strengthens interpretation within this experiment while leaving other formulations and interactions open. It does not establish that all terpene profiles are identical. A claim about a particular strain needs its own composition and a relevant outcome comparison, rather than borrowing a mean or maximum from a different product collection.
Related analysis: the study’s main findings and limitations.
Research cited
Kumar and colleagues. The Individual and Interactive Effects of Alpha-Pinene and Delta-9-Tetrahydrocannabinol in Healthy Adults. Medical Cannabis and Cannabinoids (2025). DOI: 10.1159/000547014.
